Mediar Therapeutics Secures $76M to Advance Fibrosis Therapies
January 8, 2026, 3:31 pm
Mediar Therapeutics secured a substantial $76 million in Series B financing. This Boston-based biotechnology firm is advancing novel, first-in-class therapies to combat fibrosis. The funding fuels its clinical pipeline. Key programs include MTX-474 for systemic sclerosis, now in Phase 2a trials, and MTX-439 targeting chronic kidney disease fibrosis, soon entering Phase 1. An additional program, MTX-463 for idiopathic pulmonary fibrosis, is already in global Phase 2a studies through a partnership with Eli Lilly. With this latest investment, Mediar has raised a total of $175 million. These funds accelerate the development of critical treatments. They aim to halt fibrosis progression, addressing significant unmet medical needs across various organ systems like skin, lung, and kidney.
Mediar Therapeutics, a clinical-stage biotechnology company, recently closed an oversubscribed Series B financing round. The company raised an impressive $76 million. This capital infusion propels its pioneering efforts against fibrosis. Fibrosis represents a major medical challenge. It involves the excessive scarring of tissues. This scarring ultimately leads to organ failure.
The latest funding round was co-led by prominent investors. Amplitude Ventures and ICG took the lead. New investors also joined the syndicate. These included Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Trust. Existing Series A investors reaffirmed their commitment, participating in this round. The investment highlights strong confidence in Mediar's innovative approach to fibrosis treatment. New expertise also joined the board. Bharat Srinivasa from Amplitude Ventures and Allan Marchington from ICG now serve as directors.
Mediar Therapeutics is redefining the fight against fibrotic diseases. Its strategy targets the myofibroblast. This cell is central to fibrosis development. Myofibroblasts drive scarring. They cause disease progression. Ultimately, they lead to organ failure. Halting their activity offers a new therapeutic pathway. Mediar develops first-in-class therapies. These are designed specifically to stop fibrosis at its source.
The new funds will primarily support clinical development. Mediar's wholly owned assets will advance further. This includes MTX-474. MTX-474 is an antagonist of EphrinB2. It is currently under investigation in a Phase 2a study. This trial focuses on patients suffering from systemic sclerosis (SSc). SSc is a chronic autoimmune disease. It causes widespread fibrosis.
The EncompaSSc trial is Mediar’s Phase 2a study for MTX-474. This trial is randomized and double-blinded. It is placebo-controlled. The study spans 24 weeks. Approximately 90 patients living with SSc are enrolled. Its primary goal is to evaluate efficacy, safety, and tolerability. The Modified Rodnan Skin Score (mRSS) serves as the primary endpoint. This is a validated tool. It measures skin involvement in SSc patients. The trial aims to demonstrate MTX-474’s potential to significantly impact this debilitating disease.
Another key program benefiting from the financing is MTX-439. This compound is a SMOC2 antagonist. Mediar is developing it for chronic kidney disease (CKD) associated fibrosis. CKD represents a growing public health burden. Fibrosis is a major driver of CKD progression. The company is finalizing its Investigational New Drug (IND)-enabling package for MTX-439. Plans are in place to initiate Phase 1 studies in the first half of 2026. This move promises new treatment options for a critical condition.
Mediar's pipeline also includes MTX-463. This program targets idiopathic pulmonary fibrosis (IPF). IPF is a severe, progressive lung disease. It has limited treatment options. MTX-463 is currently enrolling patients in a global Phase 2a study. This specific program operates through a partnership with Eli Lilly and Company. This collaboration underscores the broad recognition of Mediar's scientific platforms.
The total capital raised by Mediar Therapeutics through recent transactions now stands at $175 million. This includes the Series B financing and the Eli Lilly partnership deal. This substantial funding positions Mediar as a leader in anti-fibrotic drug development. It empowers the company to accelerate its ambitious clinical programs. The focus remains on bringing life-changing therapies to patients. These patients suffer from fibrosing diseases affecting the skin, lung, and kidney.
Fibrotic diseases pose immense challenges. They can be progressive and life-threatening. Current treatments often fall short. Mediar's innovative, direct targeting of the myofibroblast offers significant promise. This approach represents a paradigm shift. It moves beyond symptom management. It aims to halt the fundamental disease process. Such medical breakthroughs are urgently needed. They could transform patient outcomes globally.
Mediar Therapeutics continues its mission. It seeks to translate deep scientific understanding into novel clinical advances. The company's robust pipeline reflects this commitment. Its strategic partnerships further strengthen its position. This latest financing round marks a pivotal moment. It signals accelerated progress toward vital therapies. The global medical community watches with anticipation. New hope emerges for those battling relentless fibrotic conditions.
Mediar Therapeutics, a clinical-stage biotechnology company, recently closed an oversubscribed Series B financing round. The company raised an impressive $76 million. This capital infusion propels its pioneering efforts against fibrosis. Fibrosis represents a major medical challenge. It involves the excessive scarring of tissues. This scarring ultimately leads to organ failure.
The latest funding round was co-led by prominent investors. Amplitude Ventures and ICG took the lead. New investors also joined the syndicate. These included Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Trust. Existing Series A investors reaffirmed their commitment, participating in this round. The investment highlights strong confidence in Mediar's innovative approach to fibrosis treatment. New expertise also joined the board. Bharat Srinivasa from Amplitude Ventures and Allan Marchington from ICG now serve as directors.
Mediar Therapeutics is redefining the fight against fibrotic diseases. Its strategy targets the myofibroblast. This cell is central to fibrosis development. Myofibroblasts drive scarring. They cause disease progression. Ultimately, they lead to organ failure. Halting their activity offers a new therapeutic pathway. Mediar develops first-in-class therapies. These are designed specifically to stop fibrosis at its source.
The new funds will primarily support clinical development. Mediar's wholly owned assets will advance further. This includes MTX-474. MTX-474 is an antagonist of EphrinB2. It is currently under investigation in a Phase 2a study. This trial focuses on patients suffering from systemic sclerosis (SSc). SSc is a chronic autoimmune disease. It causes widespread fibrosis.
The EncompaSSc trial is Mediar’s Phase 2a study for MTX-474. This trial is randomized and double-blinded. It is placebo-controlled. The study spans 24 weeks. Approximately 90 patients living with SSc are enrolled. Its primary goal is to evaluate efficacy, safety, and tolerability. The Modified Rodnan Skin Score (mRSS) serves as the primary endpoint. This is a validated tool. It measures skin involvement in SSc patients. The trial aims to demonstrate MTX-474’s potential to significantly impact this debilitating disease.
Another key program benefiting from the financing is MTX-439. This compound is a SMOC2 antagonist. Mediar is developing it for chronic kidney disease (CKD) associated fibrosis. CKD represents a growing public health burden. Fibrosis is a major driver of CKD progression. The company is finalizing its Investigational New Drug (IND)-enabling package for MTX-439. Plans are in place to initiate Phase 1 studies in the first half of 2026. This move promises new treatment options for a critical condition.
Mediar's pipeline also includes MTX-463. This program targets idiopathic pulmonary fibrosis (IPF). IPF is a severe, progressive lung disease. It has limited treatment options. MTX-463 is currently enrolling patients in a global Phase 2a study. This specific program operates through a partnership with Eli Lilly and Company. This collaboration underscores the broad recognition of Mediar's scientific platforms.
The total capital raised by Mediar Therapeutics through recent transactions now stands at $175 million. This includes the Series B financing and the Eli Lilly partnership deal. This substantial funding positions Mediar as a leader in anti-fibrotic drug development. It empowers the company to accelerate its ambitious clinical programs. The focus remains on bringing life-changing therapies to patients. These patients suffer from fibrosing diseases affecting the skin, lung, and kidney.
Fibrotic diseases pose immense challenges. They can be progressive and life-threatening. Current treatments often fall short. Mediar's innovative, direct targeting of the myofibroblast offers significant promise. This approach represents a paradigm shift. It moves beyond symptom management. It aims to halt the fundamental disease process. Such medical breakthroughs are urgently needed. They could transform patient outcomes globally.
Mediar Therapeutics continues its mission. It seeks to translate deep scientific understanding into novel clinical advances. The company's robust pipeline reflects this commitment. Its strategic partnerships further strengthen its position. This latest financing round marks a pivotal moment. It signals accelerated progress toward vital therapies. The global medical community watches with anticipation. New hope emerges for those battling relentless fibrotic conditions.